Affiliation:
1. Division of Nephrology, I. Department of Medicine University Medical Center of the Johannes Gutenberg University Mainz Germany
2. Miltenyi Biotec B.V. & Co. KG Teterow Germany
3. Miltenyi Biotec B.V. & Co. KG Bergisch Gladbach Germany
4. Research Center for Immunotherapy (FZI) University Medical Center of the Johannes Gutenberg‐University Mainz Germany
Abstract
AbstractBackgroundGene therapies based on adeno‐associated viruses (AAV) are a therapeutic option to successfully treat monogenetic diseases. However, the influence of pre‐existing immunity to AAV can compromise the application of AAV gene therapy, most notably by the presence of neutralizing antibodies (NAb) to AAV.MethodsIn the following study, we investigated to what extent the treatment by immunoadsorption (IA) would reduce the levels of human anti‐AAV antibodies to AAV2 and AAV5. To that end, we screened blood sera from 40 patients receiving IA treatment because of underlying autoimmune disease or transplant rejection, with detectable AAV‐antibodies in 23 patients (22 by NAb detection, and 1 additionally by anti‐AAV5 ELISA analysis).ResultsOur results show that IA efficiently depleted anti‐AAV2 NAb with a mean reduction of 3.92 ± 1.09 log2 titer steps (93.4%) after three to five single IA treatments, 45% of seropositive subjects had an anti‐AAV2 titer below the threshold titer of 1:5 after the IA treatment series. Anti‐AAV5 NAb were reduced to below the threshold titer of 1:5 in all but one of five seropositive subjects. Analysis of total anti‐AAV5 antibodies by ELISA demonstrated an anti‐AAV5 antibody reduction over the IA treatment series of 2.67 ± 1.16 log2 titer steps (84.3%).ConclusionIn summary, IA may represent a safe strategy to precondition patients with pre‐existing anti‐AAV antibodies to make this population eligible for an effective AAV‐based gene therapy.
Subject
Hematology,General Medicine
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献